Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/3033
Title: EVALUATION OF THE SYNTHESIZED NOVEL IRIDIUM (III) COMPLEXES AGAINST HELA CELL LINES THROUGH IN-SILICO, IN-VITRO AND DNA NICKING
Authors: Sathya Priyadarshini G
Aathi, Muthusankar
Ramesh, Subramani
Selvi, Gopal
Keywords: Iridium complexes
quinoline schiff base
molecular docking
DNA nicking
Issue Date: 22-Feb-2021
Publisher: Shahid Beheshti University of Medical Sciences
Abstract: Globally, the pharmaceutical industry is continuously driven in search of new anticancer drugs due to increasing rate of cancer patients. Clinical trials of Cisplatin has been explored, however, usage of Cisplatin as a drug is limited due to its various side effects, hence, alternative to platinum based complex drugs and its analogues are needed. Iridium complexes have been attracted widespread interests by virtue of their pharmacological and photo-physical properties; however the less number of complexes was reported in the literature. In this article, a new series of novel Iridium (III) complexes were synthesized using substituted quinoline Schiff Base (SB) ligands and characterized by spectroscopic techniques. The in- vitro cyto-toxicity assay showed that the Iridium (III) complex activity is equal to standard Cisplatin. In addition, computational docking studies have shown that the prominent binding sites for synthesized complexes against HeLa cell lines, which is comparable with standard Cisplatin drugs and other Ruthenium complexes.
URI: https://journal.waocp.org/article_89473_b81e74c1d888255e6d76b4bd22307fa9.pdf
Appears in Collections:National Journals



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.